58 GSK Annual Report 2018 Group financial review continued Financial position and resources 2018 2017 Property, plant and equipment m m Assets Our business is science-based, technology-intensive and highly Non-current assets regulated by governmental authorities.
We allocate significant Property, plant and equipment 11,058 10,860 financial resources to the renewal and maintenance of our property, plant and equipment to minimise risks of interruption to production Goodwill 5,789 5,734 and to ensure compliance with regulatory standards.
A number of our Other intangible assets 17,202 17,562 processes use hazardous materials.
Investments in associates and joint ventures 236 183 The total cost of our property, plant and equipment at 31 December Other investments 1,322 918 2018 was 22,488 million, with a net book value of 11,058 million.
Deferred tax assets 3,887 3,796 Of this, land and buildings represented 4,404 million, plant and Derivative financial instruments 69 8 equipment 4,582 million and assets in construction 2,072 million.
Other non-current assets 1,576 1,413 In 2018, we invested 1,358 million in new property, plant and Total non-current assets 41,139 40,474 equipment.
This was mainly related to a large number of projects for the renewal, improvement and expansion of facilities at various Current assets worldwide sites to support new product development and launches Inventories 5,476 5,557 as well as to improve the efficiency of existing supply chains.
Current tax recoverable 229 258 Property is mainly held freehold.
New investment is financed from Trade and other receivables 6,423 6,000 our liquid resources.
At 31 December 2018, we had contractual Derivative financial instruments 188 68 commitments for future capital expenditure of 665 million and Liquid investments 84 78 operating lease commitments of 1,138 million.
We believe that our property and plant facilities are adequate for our current needs.
Cash and cash equivalents 3,874 3,833 Assets held for sale 653 113 We observe stringent procedures and use specialist skills to Total current assets 16,927 15,907 manage environmental risks from our activities.
Environmental issues, Total assets 58,066 56,381 sometimes dating from operations now modified or discontinued, are reported under Environment on page 32 and in Note 45 to the Liabilities financial statements, Legal proceedings.
Current liabilities Goodwill Short-term borrowings 5,793 2,825 Contingent consideration liabilities 837 1,076 Goodwill increased to 5,789 million at 31 December 2018, from Trade and other payables 14,037 20,970 5,734 million.
The increase primarily reflected the impact of Derivative financial instruments 127 74 exchange movements, partly offset by the transfer of goodwill to assets held for sale.
Current tax payable 965 995 Short-term provisions 732 629 Other intangible assets Total current liabilities 22,491 26,569 Other intangible assets include the cost of intangibles acquired Non-current liabilities from third parties and computer software.
The net book value of Long-term borrowings 20,271 14,264 other intangible assets as at 31 December 2018 was 17,202 million Corporation tax payable 272 411 2017 17,562 million.
The decrease in 2018 reflected the impact Deferred tax liabilities 1,156 1,396 of amortisation and impairment of existing intangibles of 902 million and 134 million respectively, partly offset by the development Pensions and other post-employment benefits 3,125 3,539 costs capitalised during the year of 203 million, other additions Other provisions 691 636 of 327 million and the impact of exchange movements.
Derivative financial instruments 1 Contingent consideration liabilities 5,449 5,096 Investments in associates and joint ventures Other non-current liabilities 938 981 We held investments in associates and joint ventures with a carrying Total non-current liabilities 31,903 26,323 value at 31 December 2018 of 236 million 2017 183 million.
Total liabilities 54,394 52,892 The market value at 31 December 2018 was 487 million Net assets 3,672 3,489 2017 372 million.
The largest of these investments was in Innoviva Inc. which had a book value at 31 December 2018 of Equity 189 million 2017 147 million.
The market value at 31 December Share capital 1,345 1,343 2018 was 440 million.
See Note 20 to the financial statements, Share premium account 3,091 3,019 Investments in associates and joint ventures.
Retained earnings 2,137 6,477 Other reserves 2,061 2,047 Shareholders equity 4,360 68 Non-controlling interests 688 3,557 Total equity 3,672 3,489 59 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information Financial position and resources continued Other investments Provisions We held other investments with a carrying value at 31 December We carried deferred tax provisions and other short-term and 2018 of 1,322 million 2017 918 million.
The highest value non-current provisions of 2,579 million at 31 December 2018 investment held at 31 December 2018 was in 23andMe, which was 2017 2,661 million.
Other provisions at the year-end included acquired during the year and had a book value at 31 December 2018 219 million 2017 186 million related to legal and other disputes of 229 million, and Theravance Biopharma, Inc. which had a book and 641 million 2017 504 million related to Major restructuring value at 31 December 2018 of 194 million 2017 199 million.
Provision has been made for legal and other disputes, The other investments included equity stakes in companies with indemnified disposal liabilities, employee related liabilities and the which we have research collaborations, which provide access to costs of the restructuring programme to the extent that at the balance biotechnology developments of potential interest and interests in sheet date a legal or constructive obligation existed and could be companies that arise from business divestments.
Derivative financial instruments: assets Pensions and other post-employment benefits We had current derivative financial assets held at fair value of 188 We account for pension and other post-employment arrangements million 2017 68 million and non-current derivative financial assets in accordance with IAS 19.
The deficits, net of surpluses, before held at fair value of 69 million 2017 8 million.
100 million of allowing for deferred taxation were 995 million 2017 1,505 current derivative financial assets related to a derivative embedded million on pension arrangements and 1,379 million 2017 1,496 in the agreement to divest Horlicks and other nutritional brands to million on unfunded post-employment liabilities.
The decrease in net Unilever plc.
See Note 38 for further information.
The majority of the deficit was predominantly driven by higher discount rates that we remainder of these financial instruments related to foreign exchange used to discount the value of the liabilities, partly offset by a reduction contracts both designated and not designated as accounting hedges.
Inventories Other non-current liabilities Inventory of 5,476 million decreased from 5,557 million in 2017.
Other non-current liabilities amounted to 938 million at The decrease primarily reflected tight control of inventory levels.
Trade and other receivables Contingent consideration liabilities Trade and other receivables of 6,423 million increased from Contingent consideration amounted to 6,286 million at 31 December 6,000 million in 2017, primarily reflecting the impact of higher sales, 2018 2017 6,172 million, of which 5,937 million 2017 5,542 particularly in Vaccines, partly offset by better collections, together million represented the estimated present value of amounts payable to with exchange movements.
Shionogi relating to ViiV Healthcare and 296 million 2017 584 million represented the estimated present value of contingent Deferred tax assets consideration payable to Novartis related to the Vaccines acquisition following a milestone payment of $450 million made to Novartis in Deferred tax assets amounted to 3,887 million 2017 January 2018.
The liability due to Shionogi included 252 million in respect of Derivative financial instruments: liabilities preferential dividends.
The liability for preferential dividends due to Pfizer at 31 December 2018 was 15 million 2017 17 million.
We held current and non-current derivative financial liabilities at fair An explanation of the accounting for the non-controlling interests value of 128 million 2017 74 million.
This primarily related to in ViiV Healthcare is set out on page 41. foreign exchange contracts both designated and not designated as Of the contingent consideration payable on a post-tax basis accounting hedges.
at 31 December 2018, 837 million 2017 1,076 million Trade and other payables is expected to be paid within one year.
The consideration payable for the acquisition of the Shionogi-ViiV Healthcare joint venture and At 31 December 2018, trade and other payables were 14,037 the Novartis Vaccines business is expected to be paid over a number million compared with 20,970 million at 31 December 2017. of years.
As a result, the total estimated liabilities are discounted to The decrease primarily reflected the elimination of the Consumer their present values, on a post-tax basis using post-tax discount Healthcare Joint Venture put option following the buyout of Novartis rates.
The Shionogi-ViiV Healthcare contingent consideration liability interest in the Consumer Healthcare Joint Venture on 1 June 2018. is discounted at 8.5% and the Novartis Vaccines contingent The buyout was primarily funded by utilising the proceeds of bonds consideration liability is discounted partly at 8% and partly at 9%.
issued with maturity dates of between two and twelve years, in both the US and Europe, which raised $6 billion and 2.5 billion respectively.
Committed bank facilities financed the remaining amount of the $13 billion transaction.
60 GSK Annual Report 2018 Group financial review continued Financial position and resources continued Maturity profile of long-term debt m equivalent 3,000 2,500 2,000 1,500 1,000 500 0 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2033 2034 2038 2039 2042 2043 2045 GBP bonds EUR bonds USD bonds Other long-term debt Cash and liquid investments of 2.9 billion 2017 2.5 billion were Net debt held centrally at 31 December 2018.
2018 2017 The analysis of cash and gross debt after the effects of hedging m m is as follows.
Cash, cash equivalents and liquid investments 3,958 3,911 2018 2017 Cash, cash equivalents reported in assets m m held for sale 485 Cash and liquid investments 4,443 3,911 Borrowings repayable within one year 5,793 2,825 1 Gross debt fixed 21,603 16,229 Borrowings repayable after one year 20,271 14,264 floating 4,432 805 Net debt 21,621 13,178 non-interest bearing 29 55 At 31 December 2018, net debt was 21.6 billion, compared with Net debt 21,621 13,178 13.2 billion at 31 December 2017, comprising gross debt of 26.1 1 Includes 1.3 billion equivalent of notes swapped from floating to fixed rates via interest billion and cash and liquid investments of 4.5 billion, including 0.5 rate swaps.
billion reported within Assets held for sale, reflecting the agreement to divest Horlicks and the other Consumer Healthcare nutritional brands Movements in net debt to Unilever plc.
Net debt increased due to the 9.3 billion acquisition from Novartis of the remaining stake in the Consumer Healthcare Joint 2018 2017 Venture in June 2018, the 0.2 billion investment in 23andMe, 0.8 m m billion of unfavourable exchange impacts from the translation of Net debt at beginning of year 13,178 13,804 non-Sterling denominated debt, and dividends paid to shareholders Increase decrease in cash and bank overdrafts 479 905 of 3.9 billion, partly offset by increased free cash flow of 5.7 billion Increase in liquid investments 4 after the milestone payment to Novartis.
Increase in long-term loans 10,138 2,233 At 31 December 2018, GSKs cash and liquid investments were held Net repayment of short-term loans 1,986 3,200 as follows: Exchange movements 776 585 2018 2017 Other movements 6 17 m m Net debt at end of year 21,621 13,178 Bank balances and deposits 1,853 1,715 Bank balances and deposits reported in assets held for sale 485 US Treasury and Treasury repo only money market funds 449 1,715 Liquidity funds 1,572 403 Cash and cash equivalents 4,359 3,833 Liquid investments Government securities 84 78 4,443 3,911 61 GSK Annual Report 2018 Strategic report Governance and remuneration Financial statements Investor information Financial position and resources continued Total equity Commitments and contingent liabilities At 31 December 2018, total equity had increased from 3,489 million Financial commitments are summarised in Note 41 to the financial at 31 December 2017 to 3,672 million.
This primarily reflected the statements, Commitments.
Other contingent liabilities are set out impact of Total profit and the re-measurement gains on defined in Note 32 to the financial statements, Contingent liabilities.
benefit plans offset by dividends paid and an unfavourable exchange Contractual obligations and commitments translation impact in the year.
A summary of the movements in equity is set out below.
The following table sets out our contractual obligations and 2018 2017 commitments at 31 December 2018 as they fall due for payment.
m m Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs Total equity at beginning of year 3,489 4,963 m m m m m Implementation of IFRS 15 4 Loans 26,154 5,771 3,367 3,562 13,454 Implementation of IFRS 9 11 Interest on loans 9,418 714 1,383 1,187 6,134 Total equity at beginning of year, as adjusted 3,474 4,963 Finance lease obligations 68 24 29 9 6 Total comprehensive income for the year 4,300 2,882 Finance lease charges 16 5 3 3 5 Dividends to shareholders 3,927 3,906 Operating lease Ordinary shares issued 74 56 commitments 1,138 223 316 228 371 Changes in non-controlling interests 2 Intangible assets 4,762 172 420 743 3,427 fide-recognition of liabilities with non-controlling Property, plant & equipment 665 560 105 interests 62 Investments 82 38 32 12 Shares acquired by ESOP Trusts 65 Purchase commitments 561 436 124 1 Share-based incentive plans 360 333 Pensions 238 75 119 44 Tax on share-based incentive plans 2 4 Total 43,102 8,018 5,898 5,789 23,397 Contributions from non-controlling interests 21 21 Commitments in respect of loans and future interest payable on loans Distributions to non-controlling interests 570 789 are disclosed before taking into account the effect of derivatives.
Total equity at end of year 3,672 3,489 We have entered into a number of research collaborations to develop new compounds with other pharmaceutical companies.
The terms Share purchases of these arrangements can include upfront fees, equity investments, No shares were acquired by the Employee Share Ownership Plan loans and commitments to fund specified levels of research.
In ESOP Trusts in 2018 2017 65 million.
Shares are held by the addition, we will often agree to make further payments if future Trusts to satisfy future exercises of options and awards under the milestones are achieved.
Group share option and award schemes.
A proportion of the shares As some of these agreements relate to compounds in the early held by the Trusts are in respect of awards where the rules of the stages of development, the potential obligation to make milestone scheme require us to satisfy exercises through market purchases payments will continue for a number of years if the compounds move rather than the issue of new shares.
The shares held by the Trusts successfully through the development process.
Generally, the closer are matched to options and awards granted.
the product is to marketing approval, the greater the probability At 31 December 2018, the ESOP Trusts held 41.5 million of success.
The amounts shown above within intangible assets 2017 66.7 million GSK shares against the future exercise of represent the maximum that would be paid if all milestones were share options and share awards.
The carrying value of 161 million achieved, and include 4.2 billion which relates to externalised 2017 400 million has been deducted from other reserves.
The projects in the discovery portfolio.
There was a reduction in the market value of these shares was 619 million 2017 882 million.
commitments in 2018 due to amendments made to existing agreements and obligations which have ceased.
During 2018, no shares were repurchased by the company.
At 31 December 2018, GSK held 414.6 million shares as Treasury In 2018, we reached a revised agreement with the trustees of the shares 2017 414.6 million shares, at a cost of 5,800 million UK pension schemes to make additional contributions, to assist in 2017 5,800 million, which has been deducted from retained eliminating the pension deficit identified as part of the 31 December earnings.
The table above includes this commitment but excludes the normal ongoing annual funding No ordinary shares were purchased in the period 1 January 2019 requirement in the UK of approximately 140 million.
This funding to 1 March 2019 and the company does not expect to make any commitment supersedes the previous agreement made in 2016. ordinary share repurchases in the remainder of 2019.
For further information on pension obligations, see Note 28 to the financial statements, Pensions and other post-employment benefits.
